Sugi Predict

Sugi Predict / Compounds / SCHEMBL4998767

SCHEMBL4998767

SCHEMBL4998767

CCc1cccc(NC=C2C(=O)Nc3ccc(Cl)cc32)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.52
▸ TDO2 P48775 2/20 0.52
▸ TGM2 P21980 2/20 0.51
▸ CDYL2 Q8N8U2 1/20 0.48
▸ CDYL Q9Y232 1/20 0.48
▸ CDY1; CDY1B Q9Y6F8 1/20 0.48
▸ LRRK2 Q5S007 5/20 0.48
▸ NTRK1 P04629 1/20 0.47
▸ PDGFRB P09619 1/20 0.46
▸ RPS6KA3 P51812 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ S1PR4 O95977 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ NTSR1 P30989 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998764 1.00 IDO1 (0.52) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4987869 0.88 IDO1 (0.56) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4987873 0.88 IDO1 (0.56) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4990700 0.86 KDR (0.49) TGM2NTRK1RPS6KA3MAPTS1PR4
SCHEMBL4990704 0.86 KDR (0.49) TGM2NTRK1RPS6KA3MAPTS1PR4
SCHEMBL4993949 0.84 ZAP70 (0.51) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4993945 0.84 ZAP70 (0.51) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4995587 0.83 LRRK2 (0.64) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4995579 0.83 LRRK2 (0.64) IDO1TDO2TGM2CDYL2CDYL
SCHEMBL4996672 0.82 LRRK2 (0.55) IDO1TDO2TGM2CDYL2CDYL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 — — US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 — — US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 — — US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 — — US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 — — US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 — — US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 — — US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 — — US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 — — US disclosed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 — — EP disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 — — US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 — — US disclosed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.